Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: Final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups

Annals of Hematology

Volumn 91, Issue 6, 2012, Pages 825-835

  Hengeveld, Marysia ^a   Suciu, Stefan ^b   Karrasch, Matthias ^b   Specchia, Giorgina ^c   Marie, Jean Pierre ^d   Muus, Petra ^a   Petti, Maria C ^e   Rotoli, Bruno ^f   Amadori, Sergio ^g   Fioritoni, Guiseppe ^h   Leoni, Pietro ⁱ   Morra, Enrica ^j   Thaler, Joseph ^k   Resegotti, Luigi ^l   Fazi, Paola ^m   Vignetti, Marco ^m   Mandelli, Franco ^e   Zittoun, Robert ^d   De Witte, Theo ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b EORTC DATA CENTER   (Belgium)

^c Policlinico Bari   (Italy)

^d HÔTEL DIEU   (France)

^e Sapienza   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g S EUGENIO HOSPITAL   (Italy)

^h Ospedale Civile di Pescara   (Italy)

ⁱ OSPEDALI RIUNITI   (Italy)

^j OSPEDALE NIGUARDA CA GRANDA   (Italy)

^k UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^l Le Molinette   (Italy)

^m GIMEMA Data Center   (Italy)

more..

Author keywords

Acute myeloid leukaemia; Post remission chemotherapy

Indexed keywords

AMSACRINE; CYTARABINE; DAUNORUBICIN; IDARUBICIN; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLEEDING; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSOLIDATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOPENIA; DIARRHEA; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; INFECTION; INTENSIVE CARE; LIVER TOXICITY; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME;

ADOLESCENT; ADULT; AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CONSOLIDATION CHEMOTHERAPY; EUROPE; FEMALE; HEMATOLOGY; HUMANS; INDUCTION CHEMOTHERAPY; INTERNATIONAL COOPERATION; ITALY; LEUKEMIA, MYELOID, ACUTE; MAINTENANCE CHEMOTHERAPY; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; SOCIETIES, MEDICAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862705582     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1436-z     Document Type: Article

References (35)

1. Schiller G, Gajewski J, Territo M, Nimer S, Lee M, Belin T et al (1992) Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 80(12):2977-2982 (Pubitemid 23004500)
2. Tallman MS, Gilliland DG, Rowe JM (2005) Drug therapy for acute myeloid leukemia. Blood 106(4):1154-1163 (Pubitemid 41130866)
3. Keating S, Suciu S, de Witte T, Mandelli F, Willemze R, Resegotti L et al (1996) Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) Leukemia Cooperative Groups. Bone Marrow Transplant 17(6):993-1001
4. Milligan DW, Grimwade D, Cullis JO, Bond L, Swirsky D, Craddock C et al (2006) Guidelines on the management of acute myeloid leukaemia in adults. Br J Haematol 135(4):450-474 (Pubitemid 44596187)
5. Zittoun R, Jehn U, Fiere D, Haanen C, Lowenberg B, Willemze R et al (1989) Alternating v repeated post-remission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group. Blood 73(4):896-906 (Pubitemid 19078365)
6. Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM et al (2007) Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 109 (9):3658-3666 (Pubitemid 46641712)
7. Estey E, Dohner H (2006) Acute myeloid leukaemia. Lancet 368 (9550):1894-1907 (Pubitemid 44794525)
8. Bradstock KF, Matthews JP, Lowenthal RM, Baxter H, Catalano J, Brighton T et al (2005) A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood 105 (2):481-488 (Pubitemid 40070725)
9. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE (2001) Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 98(5):1302-1311
10. Stone RM (2002) The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin 52(6):363-371 (Pubitemid 35446607)
11. Baer MR, George SL, Dodge RK, O'Loughlin KL, Minderman H, Caligiuri MA et al (2002) Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100(4):1224-1232 (Pubitemid 34864276)
12. Estey EH (2000) How I treat older patients with AML. Blood 96 (5):1670-1673 (Pubitemid 30661044)
13. Lowenberg B, Suciu S, Archimbaud E, Ossenkoppele G, Verhoef GE, Vellenga E et al (1997) Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood 90(8):2952-2961
14. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman PP et al (2001) Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 98(3):548-553
15. Hiddemann W, Kern W, Schoch C, Fonatsch C, Heinecke A, Wormann B et al (1999) Management of acute myeloid leukemia in elderly patients. J Clin Oncol 17(11):3569-3576 (Pubitemid 29517929)
16. Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM et al (1992) Varying intensity of postremission therapy in acute myeloid leukemia. Blood 79(8):1924-1930
17. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P et al (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331(14):896-903 (Pubitemid 24299870)
18. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R et al (1998) Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58 (18):4173-4179 (Pubitemid 28440576)
19. Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP et al (1996) A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 88(8):2841-2851 (Pubitemid 26357364)
20. Fopp M, Fey MF, Bacchi M, Cavalli F, Gmuer J, Jacky E et al (1997) Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 8(3):251-257 (Pubitemid 27153491)
21. Wolff SN, Marion J, Stein RS, Flexner JM, Lazarus HM, Spitzer TR et al (1985) High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: a pilot study. Blood 65(6):1407-11 (Pubitemid 15057947)
22. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L et al (1995) Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 332(4):217-23
23. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al (1985) Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103 (4):620-5
24. de Witte T, Suciu S, Selleslag D, Labar B, Roozendaal K, Zittoun R et al (1996) Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group. Ann Hematol 72(3):119-24
25. Zittoun R, Suciu S, Mandelli F, de Witte T, Thaler J, Stryckmans P et al (1996) Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 14(7):2150-9 (Pubitemid 26230119)
26. Yates J, Glidewell O, Wiernik P, Cooper MR, Steinberg D, Dosik H et al (1982) Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 60(2):454-62 (Pubitemid 12048693)
27. Prentice RL, Kalbfleisch JD (2003) Mixed discrete and continuous Cox regression model. Lifetime Data Anal 9(2):195-210 (Pubitemid 39015649)
28. Buchner T, Hiddemann W, Berdel WE, Wormann B, Schoch C, Fonatsch C et al (2003) 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol 21(24):4496-504 (Pubitemid 46603514)
29. Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH et al (2011) Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 29 (4):369-77
30. Lowenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A et al (2009) High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 361(13):1235-1248
31. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM et al (2009) Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 361(13):1249-59
32. Lowenberg B, Beck J, Graux C, Van PW, Schouten HC, Verdonck LF et al (2010) Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood 115(13):2586-91
33. Breems DA, Lowenberg B (2007) Acute myeloid leukemia and the position of autologous stem cell transplantation. Semin Hematol 44(4):259-66 (Pubitemid 47599543)
34. Mandelli F, Vignetti M, Suciu S, Stasi R, Petti MC, Meloni G et al (2009) Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol 27(32):5397-403
35. Mohty M, De LH, El-Cheikh J, Ladaique P, Faucher C, Furst S et al (2009) Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a 'donor' versus 'no donor' comparison. Leukemia 23 (1):194-6